Rankin Aubrey 4
4 · Revance Therapeutics, Inc. · Filed Dec 6, 2021
Insider Transaction Report
Form 4
Rankin Aubrey
DirectorPresident, Innovation & Tech
Transactions
- Purchase
Common Stock
2021-12-03$14.43/sh+30,000$432,876→ 95,463 total
Holdings
- 154,302(indirect: By Trust)
Common Stock
- 321,611(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The price reported in Table 1, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.33 to $14.50. Mr. Rankin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F2]These shares are held by The Rankin Irrevocable Trust. Mr. Rankin is a Trustee of the Rankin Irrevocable Trust.
- [F3]These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.